Financiado en parte por Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, CeNeRx, Pharmavite, ACADIA Pharmaceuticals, Avanir Pharmaceuticals, Cerecor, FORUM Pharmaceuticals, Belvoir Media Group, Janssen Research and Development
Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. The ELATED-2 Pilot Trial
Cassano P, Petrie SR, Mischoulon D, Cusin C, Katnani H, Yeung A, De Taboada L, Archibald A, Bui E, Baer L, Chang T, Chen J, Pedrelli P, Fisher L, Farabaugh A, Hamblin MR, Alpert JE, Fava M, Iosifescu DV
Photomedicine and laser surgery · 79 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Organización sin fines de lucro
- Brain and Behavior Research Foundation
- Empresa
- Abbott Laboratories
- Empresa
- Bristol-Myers Squibb
- Empresa
- Eli Lilly and Company
- Empresa
- Pfizer
- Empresa
- AstraZeneca
- Empresa
- GlaxoSmithKline
- Empresa
- Sanofi
- Universidad u hospital
- Massachusetts General Hospital
- Empresa
- Teva Pharmaceutical Industries
- Empresa
- CeNeRx
- Empresa
- Pharmavite
- Organización sin fines de lucro
- National Alliance for Research on Schizophrenia and Depression
- Empresa
- ACADIA Pharmaceuticals
- Empresa
- Avanir Pharmaceuticals
- Empresa
- Cerecor
- Organización sin fines de lucro
- American Society of Clinical Psychopharmacology
- Empresa
- FORUM Pharmaceuticals
- Empresa
- Belvoir Media Group
- Gobierno
- National Institutes of Health
- Gobierno
- National Institute of Allergy and Infectious Diseases
- Gobierno
- National Institute of Neurological Disorders and Stroke
- Empresa
- Janssen Research and Development
- Gobierno
- NIAID NIH HHS
- Subvenciones
- Brain and Behavior Research Foundation (19159); National Institute of Allergy and Infectious Diseases (R01 AI050875); National Institute of Allergy and Infectious Diseases (R21 AI121700)
Según 24 financiadores declarados.
Publicación
- Publicado
- 2018-10-22 · Photomed Laser Surg · vol. 36 · número 12 · págs. 634–646
- Editorial
- Mary Ann Liebert, Inc.
- Citado
- 157 citas · más que el 97% de estudios similares · 5.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 62 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Laser Applications in Dentistry and Medicine · Medical and Biological Ozone Research · Migraine and Headache Studies
- Palabras clave
- Antidepressant, Major depressive disorder, Medicine, Adverse effect, Dorsolateral prefrontal cortex, Depression (economics), Neuroplasticity, Internal medicine, Prefrontal cortex, Anesthesia, Psychiatry, Mood, Cognition
- MeSH
- humans, pilot projects, double-blind method, randomized controlled trials as topic, low-level light therapy, major depressive disorder
19 autores
- Paolo Cassano🇺🇸 · autor de correspondenciaMassachusetts General Hospital; National Center for Post Traumatic Stress Disorder
- Samuel R. Petrie🇺🇸Massachusetts General Hospital
- David Mischoulon🇺🇸Massachusetts General Hospital
- Cristina Cusin🇺🇸Massachusetts General Hospital
- Husam A. Katnani🇺🇸Massachusetts General Hospital
- Albert Yeung🇺🇸Massachusetts General Hospital
- Luis De Taboada🇬🇧CURE International UK
- Abigal Archibald🇺🇸Massachusetts General Hospital
- Éric Bui🇺🇸Massachusetts General Hospital; National Center for Post Traumatic Stress Disorder
- Lee Baer🇺🇸Massachusetts General Hospital
- Trina E. Chang🇺🇸Massachusetts General Hospital
- Justin Albert Chen🇺🇸Massachusetts General Hospital
- Paola Pedrelli🇺🇸Massachusetts General Hospital
- Lauren B. Fisher🇺🇸Massachusetts General Hospital
- Amy H. Farabaugh🇺🇸Massachusetts General Hospital
- Michael R. Hamblin🇺🇸Harvard University; Massachusetts General Hospital; Harvard–MIT Division of Health Sciences and Technology
- Jonathan E. Alpert🇺🇸Massachusetts General Hospital
- Maurizio Fava🇺🇸Massachusetts General Hospital
- Dan Vlad Iosifescu🇺🇸Icahn School of Medicine at Mount Sinai
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: t-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: t-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.